Blood Biomarkers of Long COVID: A Systematic Review.
Callum ThomasMark A FaghyCorinna ChidleyBethan E PhillipsThomas BewickRuth E AshtonPublished in: Molecular diagnosis & therapy (2024)
Our data are consistent with previous findings; however, no single biomarker was sufficiently associated with LC prevalence and instead a profile of biomarkers across various physiological systems may be more clinically useful. In all, 196 studies were excluded due to a lack of an adequately healthy comparator group and/or failure to meet the WHO LC definition. This demonstrates a need for further research incorporating a universal LC definition across all disease severity groups and symptom profiles, and longitudinal data reflecting the relapsing and remitting nature of this condition. Further investigation into blood biomarkers of LC, including clear reporting of healthy comparator groups and the investigation of acute and chronic biomarker changes, within the context of medical practice, may support the development of curative/restorative approaches.
Keyphrases
- multiple sclerosis
- simultaneous determination
- healthcare
- electronic health record
- coronavirus disease
- mass spectrometry
- sars cov
- primary care
- liquid chromatography
- big data
- risk factors
- liver failure
- solid phase extraction
- disease activity
- emergency department
- rheumatoid arthritis
- rectal cancer
- systemic lupus erythematosus
- tandem mass spectrometry
- acute respiratory distress syndrome
- data analysis
- patient reported